Home / Recalls / Gilead Sciences, Inc. / D-0299-2022

D-0299-2022 Class I Terminated

Recalled by Gilead Sciences, Inc. — Foster City, CA

Recall Details

Product Type
Drugs
Report Date
January 5, 2022
Initiation Date
December 3, 2021
Termination Date
July 25, 2022
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
53,473 vials

Product Description

Veklury (remdesivir) for injection, 100 mg/vial, Single-Dose Vial, Rx only, Manufactured for: Gilead Sciences, Inc., Foster City, CA 94404, NDC 61958-2901-2

Reason for Recall

Presence of Particulate Matter: investigation into a customer complaint confirmed the presence of glass particulates.

Distribution Pattern

Nationwide in the USA

Code Information

Lots: 2141001-1A, 2141002-1A, Exp. 01/2024

Other recalls by Gilead Sciences, Inc.

  • D-0005-2025 Class I — Veklury (remdesivir) for injection, 100 mg/vial, Single-Dose Vial, Rx only, Manu (September 19, 2024)
  • D-0045-2015 Class II — Emtriva (emtricitabine) Oral Solution, 10 mg/mL, 170 mL bottles, Rx only, Manufa (October 1, 2014)
  • D-0013-2015 Class III — Truvada (200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate) tablets, (September 30, 2014)
  • D-1090-2014 Class III — Atripla (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 3 (February 19, 2014)
  • D-821-2013 Class II — AmBisome (amphotericin B) liposome for Injection, 50 mg, For Intravenous Infusio (June 20, 2013)
  • D-324-2013 Class I — Vistide (cidofovir) Injection, 375 mg (75 mg/mL), 5 mL single-use vial, Rx only, (January 31, 2013)